Clinical Trial Update: A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma [Phase 2]

View source ↗

Summary

This is an update on a Phase II clinical trial evaluating siltuximab for preventing or treating CRS/ICANs after CAR-T therapy in patients with multiple myeloma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Multiple Myeloma

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Status: RECRUITING